PubMed:8608269 / 311-679 JSONTXT

{"project":"Glycan-Motif","denotations":[{"id":"T1","span":{"begin":93,"end":101},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":93,"end":101},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T3","span":{"begin":0,"end":368},"obj":"Sentence"},{"id":"T3","span":{"begin":0,"end":368},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":93,"end":101},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"GlycoBiology-GDGDB","denotations":[{"id":"_T1","span":{"begin":44,"end":48},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00346"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T34","span":{"begin":22,"end":38},"obj":"FMAID:82742"},{"id":"_T35","span":{"begin":22,"end":38},"obj":"FMAID:196731"},{"id":"_T36","span":{"begin":89,"end":92},"obj":"FMAID:24890"},{"id":"_T37","span":{"begin":89,"end":92},"obj":"FMAID:117478"},{"id":"_T38","span":{"begin":93,"end":101},"obj":"FMAID:82801"},{"id":"_T39","span":{"begin":93,"end":101},"obj":"FMAID:196796"},{"id":"_T40","span":{"begin":180,"end":186},"obj":"FMAID:226027"},{"id":"_T41","span":{"begin":180,"end":186},"obj":"FMAID:226028"},{"id":"_T42","span":{"begin":306,"end":311},"obj":"FMAID:165448"},{"id":"_T43","span":{"begin":306,"end":311},"obj":"FMAID:67264"},{"id":"_T44","span":{"begin":312,"end":327},"obj":"FMAID:196731"},{"id":"_T45","span":{"begin":312,"end":327},"obj":"FMAID:82742"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":44,"end":48},"obj":"http://www.uniprot.org/uniprot/Q8K2A8"},{"id":"T2","span":{"begin":44,"end":48},"obj":"http://www.uniprot.org/uniprot/Q61144"},{"id":"T3","span":{"begin":113,"end":116},"obj":"http://www.uniprot.org/uniprot/A2APV2"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"GO-BP","denotations":[{"id":"T3","span":{"begin":358,"end":360},"obj":"http://purl.obolibrary.org/obo/GO_0004306"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"GO-CC","denotations":[{"id":"T6","span":{"begin":286,"end":290},"obj":"http://purl.obolibrary.org/obo/GO_0019013"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":89,"end":92},"obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":113,"end":116},"obj":"https://acgg.asia/db/lfdb/LfDB0217"},{"id":"Lectin_T4","span":{"begin":361,"end":363},"obj":"https://acgg.asia/db/lfdb/LfDB0344"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T4","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T7","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T10","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T13","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T16","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T19","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T22","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T25","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T28","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T31","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T34","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T37","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T40","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T43","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T46","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T49","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T52","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T55","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T58","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T61","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T64","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T67","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T70","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T73","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T76","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T79","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T82","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T85","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T88","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T91","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T94","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T97","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T100","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T103","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T106","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T109","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T112","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T115","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T118","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T121","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T124","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T127","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T130","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T133","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T136","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T139","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T142","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T145","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T148","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T151","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T154","span":{"begin":113,"end":116},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":89,"end":92},"obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T6","span":{"begin":83,"end":92},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0003822"}],"text":"Structural studies on oligosaccharides from alg3 mutant yeast, which lack the four upper arm mannoses donated by Man-P-Dol (where Dol is dolichol), verified that the new alpha 1,6-branch in endo H-resistant mannan in this strain is efficiently initiated in vivo on the alpha 1,3-linked core residue of the lipid-oligosaccharide form of Man5GlcNAc2 (Verostek et al., J."}